Lippincott Williams & Wilkins
Supplementary table: Reported cases in the literature on biologic agents use in FMFDiagnosisAgeSexSigns and symptomsColchicineTreatmentFollow-upClinicHLA B27MEFVMetyaset al ADDIN EN.CITE <EndNote><Cite><Author>Metyas</Author><Year>2004</Year><RecNum>12</RecNum><DisplayText><style face="superscript">13</style></DisplayText><record><rec-number>12</rec-number><foreign-keys><key app="EN" db-id="prdxpz5dfdatfnexvskxxwpqwavzd0vvwawf">12</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Metyas, S.</author><author>Arkfeld, D. G.</author><author>Forrester, D. M.</author><author>Ehresmann, G. R.</author></authors></contributors><auth-address>LAC+USC Medical Center, Los Angeles, California, USA.</auth-address><titles><title>Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>134-7</pages><volume>10</volume><number>3</number><edition>2006/10/18</edition><dates><year>2004</year><pub-dates><date>Jun</date></pub-dates></dates><isbn>1076-1608 (Print)
1076-1608 (Linking)</isbn><accession-num>17043487</accession-num><urls><related-urls><url> pain attacks , chest pain arthritis attacks, GIS symptoms amyloid arthropathy(shoulder)UInfliximab 3 mg/kg at0 ,2th,6, 8th weeks6 mDramatic improvement in 6th doseImprovement in proteinuria and acute phase responsesNeg.N/ADaysal et al ADDIN EN.CITE <EndNote><Cite><Author>Daysal</Author><Year>2005</Year><RecNum>11</RecNum><DisplayText><style face="superscript">14</style></DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="prdxpz5dfdatfnexvskxxwpqwavzd0vvwawf">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Daysal, S.</author><author>Akcil, G.</author><author>Goker, B.</author><author>Haznedaroglu, S.</author><author>Ercan, N.</author><author>Ozturk, M. A.</author></authors></contributors><titles><title>Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis</title><secondary-title>Arthritis Rheum</secondary-title></titles><periodical><full-title>Arthritis Rheum</full-title></periodical><pages>146-7</pages><volume>53</volume><number>1</number><edition>2005/02/08</edition><keywords><keyword>Adult</keyword><keyword>Antibodies, Monoclonal/*therapeutic use</keyword><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Chronic Disease</keyword><keyword>Familial Mediterranean Fever/*complications</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Osteoarthritis, Hip/*complications/*drug therapy/pathology</keyword></keywords><dates><year>2005</year><pub-dates><date>Feb 15</date></pub-dates></dates><isbn>0004-3591 (Print)
0004-3591 (Linking)</isbn><accession-num>15696552</accession-num><urls><related-urls><url> and ankle arthritis attacks, abdominal pain attacks, hip arthritis*RInfliximab 200 mg at0,2th,6th, weeks and 5 doses in 8 weeks interval6 mRapid response, Improvement in acute phase responsesM694V/M694VYuksel et al ADDIN EN.CITE <EndNote><Cite><Author>Yuksel</Author><Year>2006</Year><RecNum>7</RecNum><DisplayText><style face="superscript">15</style></DisplayText><record><rec-number>7</rec-number><foreign-keys><key app="EN" db-id="prdxpz5dfdatfnexvskxxwpqwavzd0vvwawf">7</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Yuksel, S.</author><author>Yalcinkaya, F.</author><author>Acar, B.</author><author>Ozcakar, Z. B.</author><author>Ozturk, B.</author><author>Ekim, M.</author></authors></contributors><titles><title>Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever</title><secondary-title>Rheumatology (Oxford)</secondary-title></titles><pages>1307-8</pages><volume>45</volume><number>10</number><edition>2006/08/02</edition><keywords><keyword>Amyloidosis/complications/*drug therapy</keyword><keyword>Antibodies, Monoclonal/*therapeutic use</keyword><keyword>Child</keyword><keyword>Colchicine/therapeutic use</keyword><keyword>Drug Therapy, Combination</keyword><keyword>Familial Mediterranean Fever/complications/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Immunosuppressive Agents/*therapeutic use</keyword></keywords><dates><year>2006</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1462-0324 (Print)
1462-0324 (Linking)</isbn><accession-num>16880190</accession-num><urls><related-urls><url> [pii]
10.1093/rheumatology/kel250</electronic-resource-num><language>eng</language></record></Cite></EndNote>152006FMFAmyloidosisProtracted arthritis12FBloody diarrhea, vomiting, massive proteinuria, hypoalbuminemia, knee and ankle arthritis*RInfliximab 3 mg/kg at0,2,6, 8 th weeks22 mImprovement in massive proteinuria and hypoalbuminemia,Back in schoolfull recovery in GIS symptoms and arthritisNAM694V/M680ISakall?ogluet al HYPERLINK \l "_ENREF_16" \o "Sakallioglu, 2006 #2" PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TYWthbGxpb2dsdTwvQXV0aG9yPjxZZWFyPjIwMDY8L1ll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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TYWthbGxpb2dsdTwvQXV0aG9yPjxZZWFyPjIwMDY8L1ll
YXI+PFJlY051bT45PC9SZWNOdW0+PERpc3BsYXlUZXh0PjxzdHlsZSBmYWNlPSJzdXBlcnNjcmlw
dCI+MTY8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj45PC9yZWMtbnVt
YmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0icHJkeHB6NWRmZGF0Zm5leHZz
a3h4d3Bxd2F2emQwdnZ3YXdmIj45PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9
IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1
dGhvcj5TYWthbGxpb2dsdSwgTy48L2F1dGhvcj48YXV0aG9yPkR1em92YSwgQS48L2F1dGhvcj48
YXV0aG9yPk96ZW4sIFMuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFk
ZHJlc3M+UGVkaWF0cmljIE5lcGhyb2xvZ3kgYW5kIFJoZXVtYXRvbG9neSBVbml0LCBEZXBhcnRt
ZW50IG9mIFBlZGlhdHJpY3MsIEhhY2V0dGVwZSBVbml2ZXJzaXR5IEZhY3VsdHkgb2YgTWVkaWNp
bmUsIEFua2FyYSwgVHVya2V5LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkV0YW5lcmNl
cHQgaW4gdGhlIHRyZWF0bWVudCBvZiBhcnRocml0aXMgaW4gYSBwYXRpZW50IHdpdGggZmFtaWxp
YWwgTWVkaXRlcnJhbmVhbiBmZXZlcjwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5DbGluIEV4cCBS
aGV1bWF0b2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs
ZT5DbGluIEV4cCBSaGV1bWF0b2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz40MzUt
NzwvcGFnZXM+PHZvbHVtZT4yNDwvdm9sdW1lPjxudW1iZXI+NDwvbnVtYmVyPjxlZGl0aW9uPjIw
MDYvMDkvMDg8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+
PGtleXdvcmQ+QW50aXJoZXVtYXRpYyBBZ2VudHMvKnRoZXJhcGV1dGljIHVzZTwva2V5d29yZD48
a2V5d29yZD5BcnRocml0aXMvKmRydWcgdGhlcmFweS8qZXRpb2xvZ3k8L2tleXdvcmQ+PGtleXdv
cmQ+Q29sY2hpY2luZS90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+RHJ1ZyBSZXNp
c3RhbmNlPC9rZXl3b3JkPjxrZXl3b3JkPkRydWcgVGhlcmFweSwgQ29tYmluYXRpb248L2tleXdv
cmQ+PGtleXdvcmQ+RmFtaWxpYWwgTWVkaXRlcnJhbmVhbiBGZXZlci8qY29tcGxpY2F0aW9ucy9k
cnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPklt
bXVub2dsb2J1bGluIEcvKnRoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5NYWxlPC9r
ZXl3b3JkPjxrZXl3b3JkPk1ldGhvdHJleGF0ZS90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtl
eXdvcmQ+UHJlZG5pc29sb25lL3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5SZWNl
cHRvcnMsIFR1bW9yIE5lY3Jvc2lzIEZhY3Rvci8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxr
ZXl3b3JkPlJlbWlzc2lvbiBJbmR1Y3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+VHJlYXRtZW50IE91
dGNvbWU8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwNjwveWVhcj48cHViLWRh
dGVzPjxkYXRlPkp1bC1BdWc8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMzkyLTg1
NlggKFByaW50KSYjeEQ7MDM5Mi04NTZYIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4x
Njk1NjQzNjwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3
dy5uY2JpLm5sbS5uaWguZ292L2VudHJlei9xdWVyeS5mY2dpP2NtZD1SZXRyaWV2ZSZhbXA7ZGI9
UHViTWVkJmFtcDtkb3B0PUNpdGF0aW9uJmFtcDtsaXN0X3VpZHM9MTY5NTY0MzY8L3VybD48L3Jl
bGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjE4NzUgW3BpaV08L2Vs
ZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxsYW5ndWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwv
Q2l0ZT48L0VuZE5vdGU+AG==
ADDIN EN.CITE.DATA 162006FMFJIA15MAnkle and wrist arthritisLREtanercept 0.8 mg/kg/week4 mExcellent response in the 2th doseremission for 6 months following discontinuation of 4 months treatmentNAE148Q/E148QOzgocmenet al HYPERLINK \l "_ENREF_17" \o "Ozgocmen, 2006 #41" ADDIN EN.CITE <EndNote><Cite><Author>Ozgocmen</Author><Year>2006</Year><RecNum>41</RecNum><DisplayText><style face="superscript">17</style></DisplayText><record><rec-number>41</rec-number><foreign-keys><key app="EN" db-id="pvawsssduwxrvjewxznvdx5ne99z5220vxd0">41</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ozgocmen, S.</author><author>Ozcakar, L.</author><author>Ardicoglu, O.</author><author>Kocakoc, E.</author><author>Kaya, A.</author><author>Kiris, A.</author></authors></contributors><auth-address>Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University, Elazig, Turkey. sozgocmen@</auth-address><titles><title>Familial Mediterranean fever responds well to infliximab: single case experience</title><secondary-title>Clin Rheumatol</secondary-title></titles><periodical><full-title>Clin Rheumatol</full-title></periodical><pages>83-7</pages><volume>25</volume><number>1</number><edition>2005/09/21</edition><keywords><keyword>Adult</keyword><keyword>Antibodies, Monoclonal/*therapeutic use</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Femur Head Necrosis/drug therapy/pathology/physiopathology</keyword><keyword>Gastrointestinal Agents/*therapeutic use</keyword><keyword>Humans</keyword><keyword>Magnetic Resonance Imaging</keyword><keyword>Spine/pathology</keyword><keyword>Spondylitis/drug therapy/pathology/physiopathology</keyword><keyword>Treatment Outcome</keyword><keyword>Tumor Necrosis Factor-alpha/*antagonists & inhibitors</keyword></keywords><dates><year>2006</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>0770-3198 (Print)
0770-3198 (Linking)</isbn><accession-num>16172948</accession-num><urls><related-urls><url> abdominal attacksLow back and hip painRInfliximab 3 mg/kg0,2,6, 6 th week18 mNo abdominal attacks during follow up. No improvement in hip movementsNeg.N/ASeyahiet al HYPERLINK \l "_ENREF_18" \o "Seyahi, 2006 #42" ADDIN EN.CITE <EndNote><Cite><Author>Seyahi</Author><Year>2006</Year><RecNum>16</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="prdxpz5dfdatfnexvskxxwpqwavzd0vvwawf">16</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Seyahi, E.</author><author>Ozdogan, H.</author><author>Celik, S.</author><author>Ugurlu, S.</author><author>Yazici, H.</author></authors></contributors><auth-address>Division of Rheumatology, Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey.</auth-address><titles><title>Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents</title><secondary-title>Clin Exp Rheumatol</secondary-title></titles><periodical><full-title>Clin Exp Rheumatol</full-title></periodical><pages>S99-103</pages><volume>24</volume><number>5 Suppl 42</number><edition>2006/10/28</edition><keywords><keyword>Adult</keyword><keyword>Colchicine/pharmacology</keyword><keyword>Drug Resistance</keyword><keyword>Drug Therapy, Combination</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Immunoglobulin G/*therapeutic use</keyword><keyword>Immunosuppressive Agents/*therapeutic use</keyword><keyword>Male</keyword><keyword>Receptors, Tumor Necrosis Factor/*therapeutic use</keyword><keyword>Thalidomide/*therapeutic use</keyword><keyword>Tubulin Modulators/pharmacology</keyword></keywords><dates><year>2006</year><pub-dates><date>Sep-Oct</date></pub-dates></dates><isbn>0392-856X (Print)
0392-856X (Linking)</isbn><accession-num>17067437</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>182006FMF30FAbdominal attacksUEtanercept – 2 weeksThalidomide-8.5 monthsInjection site reactionNegN/ASeyahiet al HYPERLINK \l "_ENREF_18" \o "Seyahi, 2006 #42" ADDIN EN.CITE <EndNote><Cite><Author>Seyahi</Author><Year>2006</Year><RecNum>16</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="prdxpz5dfdatfnexvskxxwpqwavzd0vvwawf">16</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Seyahi, E.</author><author>Ozdogan, H.</author><author>Celik, S.</author><author>Ugurlu, S.</author><author>Yazici, H.</author></authors></contributors><auth-address>Division of Rheumatology, Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey.</auth-address><titles><title>Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents</title><secondary-title>Clin Exp Rheumatol</secondary-title></titles><periodical><full-title>Clin Exp Rheumatol</full-title></periodical><pages>S99-103</pages><volume>24</volume><number>5 Suppl 42</number><edition>2006/10/28</edition><keywords><keyword>Adult</keyword><keyword>Colchicine/pharmacology</keyword><keyword>Drug Resistance</keyword><keyword>Drug Therapy, Combination</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Immunoglobulin G/*therapeutic use</keyword><keyword>Immunosuppressive Agents/*therapeutic use</keyword><keyword>Male</keyword><keyword>Receptors, Tumor Necrosis Factor/*therapeutic use</keyword><keyword>Thalidomide/*therapeutic use</keyword><keyword>Tubulin Modulators/pharmacology</keyword></keywords><dates><year>2006</year><pub-dates><date>Sep-Oct</date></pub-dates></dates><isbn>0392-856X (Print)
0392-856X (Linking)</isbn><accession-num>17067437</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>182006FMF40MSevere abdominal attacksUThalidomide - 2 monthsEtanercept - 8 months10 mLess severe first 3 months and disappeared thereafter, improvement acute phase responsesNAN/ASeyahiet al HYPERLINK \l "_ENREF_18" \o "Seyahi, 2006 #42" ADDIN EN.CITE <EndNote><Cite><Author>Seyahi</Author><Year>2006</Year><RecNum>16</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="prdxpz5dfdatfnexvskxxwpqwavzd0vvwawf">16</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Seyahi, E.</author><author>Ozdogan, H.</author><author>Celik, S.</author><author>Ugurlu, S.</author><author>Yazici, H.</author></authors></contributors><auth-address>Division of Rheumatology, Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey.</auth-address><titles><title>Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents</title><secondary-title>Clin Exp Rheumatol</secondary-title></titles><periodical><full-title>Clin Exp Rheumatol</full-title></periodical><pages>S99-103</pages><volume>24</volume><number>5 Suppl 42</number><edition>2006/10/28</edition><keywords><keyword>Adult</keyword><keyword>Colchicine/pharmacology</keyword><keyword>Drug Resistance</keyword><keyword>Drug Therapy, Combination</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Immunoglobulin G/*therapeutic use</keyword><keyword>Immunosuppressive Agents/*therapeutic use</keyword><keyword>Male</keyword><keyword>Receptors, Tumor Necrosis Factor/*therapeutic use</keyword><keyword>Thalidomide/*therapeutic use</keyword><keyword>Tubulin Modulators/pharmacology</keyword></keywords><dates><year>2006</year><pub-dates><date>Sep-Oct</date></pub-dates></dates><isbn>0392-856X (Print)
0392-856X (Linking)</isbn><accession-num>17067437</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>182006FMF37MSevere abdominal attacksLeg and foot painUThalidomide - 7 monthsEtanercept - 8 months15 mLess severe first 3 months and disappeared thereafter, improved leg and foot pain, Improvement acute phase responsesNAN/AMor et al HYPERLINK \l "_ENREF_19" \o "Mor, 2007 #10" ADDIN EN.CITE <EndNote><Cite><Author>Mor</Author><Year>2007</Year><RecNum>10</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>10</rec-number><foreign-keys><key app="EN" db-id="prdxpz5dfdatfnexvskxxwpqwavzd0vvwawf">10</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mor, A.</author><author>Pillinger, M. H.</author><author>Kishimoto, M.</author><author>Abeles, A. M.</author><author>Livneh, A.</author></authors></contributors><auth-address>Department of Medicine, Division of Rheumatology, New York University School of Medicine/Hospital for Joint Diseases, New York, NY 10003, USA. mora01@med.nyu.edu</auth-address><titles><title>Familial Mediterranean fever successfully treated with etanercept</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>38-40</pages><volume>13</volume><number>1</number><edition>2007/02/07</edition><keywords><keyword>Adult</keyword><keyword>Familial Mediterranean Fever/diagnosis/*drug therapy</keyword><keyword>Humans</keyword><keyword>Immunoglobulin G/*therapeutic use</keyword><keyword>Immunosuppressive Agents/*therapeutic use</keyword><keyword>Male</keyword><keyword>Receptors, Tumor Necrosis Factor/*therapeutic use</keyword><keyword>Treatment Outcome</keyword></keywords><dates><year>2007</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1076-1608 (Print)
1076-1608 (Linking)</isbn><accession-num>17278949</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>192007FMF33MKnee arthritis, oral ulcers, testicular attacksIEtanercept 25 mg twice a week36 mImprovement in the severity and frequency of arthritis attacks. No abdominal and testicular attacks during follow up.NegV726A/-Brik et al HYPERLINK \l "_ENREF_20" \o "Brik, 2007 #68" ADDIN EN.CITE <EndNote><Cite><Author>Brik</Author><Year>2007</Year><RecNum>68</RecNum><DisplayText><style face="superscript">20</style></DisplayText><record><rec-number>68</rec-number><foreign-keys><key app="EN" db-id="prdxpz5dfdatfnexvskxxwpqwavzd0vvwawf">68</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Brik, R.</author><author>Gepstein, V.</author><author>Shahar, E.</author><author>Goldsher, D.</author><author>Berkovitz, D.</author></authors></contributors><auth-address>Department of Pediatrics, Meyer Children's Hospital of Haifa, P.O. Box 9602, Technion, Haifa 31096, Israel. r_brik@rambam..il</auth-address><titles><title>Tumor necrosis factor blockade in the management of children with orphan diseases</title><secondary-title>Clin Rheumatol</secondary-title></titles><periodical><full-title>Clin Rheumatol</full-title></periodical><pages>1783-5</pages><volume>26</volume><number>10</number><edition>2007/01/16</edition><keywords><keyword>Adolescent</keyword><keyword>Arthritis, Juvenile Rheumatoid/therapy</keyword><keyword>Child</keyword><keyword>Child, Preschool</keyword><keyword>Familial Mediterranean Fever/metabolism/*therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Polyarteritis Nodosa/metabolism/*therapy</keyword><keyword>Sarcoidosis/metabolism/*therapy</keyword><keyword>Treatment Outcome</keyword><keyword>Tumor Necrosis Factor-alpha/*antagonists & inhibitors</keyword><keyword>Vasculitis/therapy</keyword></keywords><dates><year>2007</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>0770-3198 (Print)
0770-3198 (Linking)</isbn><accession-num>17219021</accession-num><urls><related-urls><url> and elbow arthritisUInfliximab 3 mg/kg at 0,2 and 6 weeks and needed (2 to 3 months)4 mResolution in the arthritis and cessation of the steroidsV726A/E148QBoduret al HYPERLINK \l "_ENREF_12" \o "Bodur, 2008 #8" PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Cb2R1cjwvQXV0aG9yPjxZZWFyPjIwMDg8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Cb2R1cjwvQXV0aG9yPjxZZWFyPjIwMDg8L1llYXI+PFJl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ADDIN EN.CITE.DATA 122008FMFPsoriasis43MHip and knee arthritisPsoriasis sacroiliitisProteinuria (amyloidosis)LRInfliximab 5 mg/kg-Improvement in BASDAI score from 6.5 to 2 at 3th infusionImprovement in proteinuriaand acute phase reactantsNegM694V/M694VKaya et al HYPERLINK \l "_ENREF_21" \o "Kaya, 2010 #31" ADDIN EN.CITE <EndNote><Cite><Author>Kaya</Author><Year>2010</Year><RecNum>31</RecNum><DisplayText><style face="superscript">21</style></DisplayText><record><rec-number>31</rec-number><foreign-keys><key app="EN" db-id="prdxpz5dfdatfnexvskxxwpqwavzd0vvwawf">31</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kaya, S.</author><author>Kaptanoglu, E.</author><author>Elden, H.</author><author>Hizmetli, S.</author></authors></contributors><auth-address>Faculty of Medicine, Department of Rheumatology, Cumhuriyet University, Sivas, Turkey.</auth-address><titles><title>Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept</title><secondary-title>Intern Med</secondary-title></titles><periodical><full-title>Intern Med</full-title></periodical><pages>619-22</pages><volume>49</volume><number>6</number><edition>2010/03/17</edition><keywords><keyword>Adult</keyword><keyword>Arthritis, Juvenile Rheumatoid/*drug therapy/epidemiology</keyword><keyword>Comorbidity</keyword><keyword>Familial Mediterranean Fever/*drug therapy/epidemiology</keyword><keyword>Follow-Up Studies</keyword><keyword>Humans</keyword><keyword>Immunoglobulin G/*therapeutic use</keyword><keyword>Immunosuppressive Agents/*therapeutic use</keyword><keyword>Male</keyword><keyword>Osteoporosis/*drug therapy/epidemiology</keyword><keyword>Receptors, Tumor Necrosis Factor/*therapeutic use</keyword><keyword>Treatment Outcome</keyword></keywords><dates><year>2010</year></dates><isbn>1349-7235 (Electronic)
0918-2918 (Linking)</isbn><accession-num>20228604</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>212010FMFJIAOsteoporosis27MWrist and small joints arthritis (erosion and ankylosing) severe abdominal attacksLREtanercept 25 mg /twice a weekMTX 15 mg /week2 mImprovement in arthritisRemission in laboratoryOnly one abdominal attack during follow upNAM694V/V726ANakamura et al HYPERLINK \l "_ENREF_22" \o "Nakamura, 2007 #69" ADDIN EN.CITE <EndNote><Cite><Author>Nakamura</Author><Year>2007</Year><RecNum>3</RecNum><DisplayText><style face="superscript">22</style></DisplayText><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="prdxpz5dfdatfnexvskxxwpqwavzd0vvwawf">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Nakamura, A.</author><author>Matsuda, M.</author><author>Tazawa, K.</author><author>Shimojima, Y.</author><author>Ikeda, S.</author></authors></contributors><auth-address>Department of Rheumatology and Collagen Disease, Shinshu University School of Medicine, Matsumoto.</auth-address><titles><title>Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever</title><secondary-title>Intern Med</secondary-title></titles><periodical><full-title>Intern Med</full-title></periodical><pages>1247-9</pages><volume>46</volume><number>15</number><edition>2007/08/07</edition><keywords><keyword>Adult</keyword><keyword>Antibodies, Monoclonal/adverse effects/immunology/*therapeutic use</keyword><keyword>Antirheumatic Agents/adverse effects/*therapeutic use</keyword><keyword>Dose-Response Relationship, Drug</keyword><keyword>Drug Therapy, Combination</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Methotrexate/*therapeutic use</keyword><keyword>Tumor Necrosis Factor-alpha/immunology</keyword></keywords><dates><year>2007</year></dates><isbn>1349-7235 (Electronic)
0918-2918 (Linking)</isbn><accession-num>17675778</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>222007FMF20FSevere abdominal attacksIInfliximab 3 mg/kg0,2,6, 8 th weekMTX 6 mg /week12 mNo abdominal attacks during follow upNAE148Q/M694IOzgocmenet al ADDIN EN.CITE <EndNote><Cite><Author>Ozgocmen</Author><Year>2011</Year><RecNum>6</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="pvawsssduwxrvjewxznvdx5ne99z5220vxd0">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ozgocmen, S.</author><author>Akgul, O.</author></authors></contributors><auth-address>Division of Rheumatology, Dept. PMR, Gevher Nesibe Hospital, Erciyes University, School of Medicine, 38039 Kayseri, Turkey. sozgocmen@</auth-address><titles><title>Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature</title><secondary-title>Mod Rheumatol</secondary-title></titles><periodical><full-title>Mod Rheumatol</full-title></periodical><pages>684-90</pages><volume>21</volume><number>6</number><edition>2011/05/14</edition><dates><year>2011</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1439-7609 (Electronic)
1439-7595 (Linking)</isbn><accession-num>21567247</accession-num><urls><related-urls><url> abdominal attacks, spinal pain,proteinuria and hypoalbuminemiaUInfliximab 3 mg/kg0,2,6, 8 or 6 th week - 36 monthsAdalimumab 40 mg every other week - 4 months40 mNo abdominal attacks during follow upImprovement in massive proteinuria and hypoalbuminemia, and spinal painPos.M694V/M694VOzgocmenet al ADDIN EN.CITE <EndNote><Cite><Author>Ozgocmen</Author><Year>2011</Year><RecNum>6</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="pvawsssduwxrvjewxznvdx5ne99z5220vxd0">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ozgocmen, S.</author><author>Akgul, O.</author></authors></contributors><auth-address>Division of Rheumatology, Dept. PMR, Gevher Nesibe Hospital, Erciyes University, School of Medicine, 38039 Kayseri, Turkey. sozgocmen@</auth-address><titles><title>Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature</title><secondary-title>Mod Rheumatol</secondary-title></titles><periodical><full-title>Mod Rheumatol</full-title></periodical><pages>684-90</pages><volume>21</volume><number>6</number><edition>2011/05/14</edition><dates><year>2011</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1439-7609 (Electronic)
1439-7595 (Linking)</isbn><accession-num>21567247</accession-num><urls><related-urls><url> abdominal attacks, spinal painUEtanercept 25mg twice a week - 6 monthsInfliximab 3 mg/kg0,2,6, 8 or 6th week -12 monthsAdalimumab 40 mg every other week - 7 months19 mImprovement in acute phase responses and spinal pain, with ADA no abdominal attacksPos.M694V/M694VOzgocmenet al ADDIN EN.CITE <EndNote><Cite><Author>Ozgocmen</Author><Year>2011</Year><RecNum>6</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="pvawsssduwxrvjewxznvdx5ne99z5220vxd0">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ozgocmen, S.</author><author>Akgul, O.</author></authors></contributors><auth-address>Division of Rheumatology, Dept. PMR, Gevher Nesibe Hospital, Erciyes University, School of Medicine, 38039 Kayseri, Turkey. sozgocmen@</auth-address><titles><title>Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature</title><secondary-title>Mod Rheumatol</secondary-title></titles><periodical><full-title>Mod Rheumatol</full-title></periodical><pages>684-90</pages><volume>21</volume><number>6</number><edition>2011/05/14</edition><dates><year>2011</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1439-7609 (Electronic)
1439-7595 (Linking)</isbn><accession-num>21567247</accession-num><urls><related-urls><url> abdominal attacks, spinal painUAdalimumab 40 mg every other week4 mNo abdominal attacks during follow up. Improvement in spinal painPos.M694V/M694VErtenet al ADDIN EN.CITE <EndNote><Cite><Author>Erten</Author><Year>2011</Year><RecNum>6</RecNum><DisplayText><style face="superscript">23</style></DisplayText><record><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Erten, S.</author><author>Erten, S. F.</author><author>Altunoglu, A.</author></authors></contributors><auth-address>Division of Rheumatology, Ataturk Education and Research Hospital, Ankara, Turkey, sukranerten@.</auth-address><titles><title>Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF</title><secondary-title>Rheumatol Int</secondary-title></titles><periodical><full-title>Rheumatol Int</full-title></periodical><edition>2011/03/25</edition><dates><year>2011</year><pub-dates><date>Mar 23</date></pub-dates></dates><isbn>1437-160X (Electronic)
0172-8172 (Linking)</isbn><accession-num>21431291</accession-num><urls><related-urls><url> 2011FMFSpondylitis35MSevere abdominal attacksSpinal painProteinuriaHypoalbumunemiaAnkle arthritisUEtanercept12 m No abdominal attacks and arthritis during follow-upProteinuria is in normal limitsNegM694V/M694VZihniEt al ADDIN EN.CITE <EndNote><Cite><Author>Zihni</Author><Year>2011</Year><RecNum>9</RecNum><DisplayText><style face="superscript">24</style></DisplayText><record><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">9</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Zihni, F. Y.</author><author>Kalfa, M.</author><author>Ocakci, P. T.</author><author>Tarhan, F.</author><author>Parildar, M.</author><author>Keser, G.</author><author>Aksu, K.</author></authors></contributors><auth-address>Division of Rheumatology, Department of Internal Medicine, Ege University School of Medicine, 80. Sk. No: 27/3, 35040, Bornova, Izmir, Turkey.</auth-address><titles><title>Coexistence of Takayasu's arteritis with familial Mediterranean fever</title><secondary-title>Rheumatol Int</secondary-title></titles><periodical><full-title>Rheumatol Int</full-title></periodical><edition>2011/03/19</edition><dates><year>2011</year><pub-dates><date>Mar 18</date></pub-dates></dates><isbn>1437-160X (Electronic)
0172-8172 (Linking)</isbn><accession-num>21416236</accession-num><urls><related-urls><url> 2011FMF Takayasu’s arteritisCutaneus vascuilitis22MFeverdizzinessUInfliximab 5mg/kg0,2,6 weeks and 8th week (6 doses)12 mImprovement clinical parameters and acute phase responsesN/AM694V/V726ABilgenet al ADDIN EN.CITE <EndNote><Cite><Author>Bilgen</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilgen, S. A.</author><author>Kilic, L.</author><author>Akdogan, A.</author><author>Kiraz, S.</author><author>Kalyoncu, U.</author><author>Karadag, O.</author><author>Ertenli, I.</author><author>Dogan, I.</author><author>Calguneri, M.</author></authors></contributors><auth-address>From the Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.</auth-address><titles><title>Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>358-62</pages><volume>17</volume><number>7</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1536-7355 (Electronic)
1076-1608 (Linking)</isbn><accession-num>21946459</accession-num><urls><related-urls><url> attacksBack painUAdalimumab 40 mg every other week 5 monthsEtanercept 25 mg twice a weekAt least 12 mAttack duration and frequency decreasedNegM694V/M694VBilgenet al ADDIN EN.CITE <EndNote><Cite><Author>Bilgen</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilgen, S. A.</author><author>Kilic, L.</author><author>Akdogan, A.</author><author>Kiraz, S.</author><author>Kalyoncu, U.</author><author>Karadag, O.</author><author>Ertenli, I.</author><author>Dogan, I.</author><author>Calguneri, M.</author></authors></contributors><auth-address>From the Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.</auth-address><titles><title>Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>358-62</pages><volume>17</volume><number>7</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1536-7355 (Electronic)
1076-1608 (Linking)</isbn><accession-num>21946459</accession-num><urls><related-urls><url> attacksBack painPeripheral arthritisproteinuriaUInfliximab 5mg/kg0,2,6 weeks and 6th-8th weekAt least 12 mAttack duration and frequency decreasedNo peripheral arthritisImprovement in proteinuriaN/AM694V/M680IBilgenet al ADDIN EN.CITE <EndNote><Cite><Author>Bilgen</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilgen, S. A.</author><author>Kilic, L.</author><author>Akdogan, A.</author><author>Kiraz, S.</author><author>Kalyoncu, U.</author><author>Karadag, O.</author><author>Ertenli, I.</author><author>Dogan, I.</author><author>Calguneri, M.</author></authors></contributors><auth-address>From the Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.</auth-address><titles><title>Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>358-62</pages><volume>17</volume><number>7</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1536-7355 (Electronic)
1076-1608 (Linking)</isbn><accession-num>21946459</accession-num><urls><related-urls><url> attacksBack painUEtanercept 25 mg twice a weekAt least 12 mAttack duration and frequency decreasedNegE148Q/E148QBilgenet al ADDIN EN.CITE <EndNote><Cite><Author>Bilgen</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilgen, S. A.</author><author>Kilic, L.</author><author>Akdogan, A.</author><author>Kiraz, S.</author><author>Kalyoncu, U.</author><author>Karadag, O.</author><author>Ertenli, I.</author><author>Dogan, I.</author><author>Calguneri, M.</author></authors></contributors><auth-address>From the Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.</auth-address><titles><title>Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>358-62</pages><volume>17</volume><number>7</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1536-7355 (Electronic)
1076-1608 (Linking)</isbn><accession-num>21946459</accession-num><urls><related-urls><url> attacksBack painLREtanercept 25 mg twice a weekAt least 12 mNo attacksN/AM694V/M680IBilgenet al ADDIN EN.CITE <EndNote><Cite><Author>Bilgen</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilgen, S. A.</author><author>Kilic, L.</author><author>Akdogan, A.</author><author>Kiraz, S.</author><author>Kalyoncu, U.</author><author>Karadag, O.</author><author>Ertenli, I.</author><author>Dogan, I.</author><author>Calguneri, M.</author></authors></contributors><auth-address>From the Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.</auth-address><titles><title>Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>358-62</pages><volume>17</volume><number>7</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1536-7355 (Electronic)
1076-1608 (Linking)</isbn><accession-num>21946459</accession-num><urls><related-urls><url> attacksBack painProteinuriaUEtanercept 25 mg twice a weekAt least 12 mNo attacksImprovement in proteinuriaN/AM694V/M694VBilgenet al ADDIN EN.CITE <EndNote><Cite><Author>Bilgen</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilgen, S. A.</author><author>Kilic, L.</author><author>Akdogan, A.</author><author>Kiraz, S.</author><author>Kalyoncu, U.</author><author>Karadag, O.</author><author>Ertenli, I.</author><author>Dogan, I.</author><author>Calguneri, M.</author></authors></contributors><auth-address>From the Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.</auth-address><titles><title>Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>358-62</pages><volume>17</volume><number>7</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1536-7355 (Electronic)
1076-1608 (Linking)</isbn><accession-num>21946459</accession-num><urls><related-urls><url> attacksBack painPeripheral arthritisLRInfliximab 5mg/kg0,2,6 weeks and 6th-8th weekAt least 12 mNo attacksNo peripheral arthritisNegM694V/V726ABilgenet al ADDIN EN.CITE <EndNote><Cite><Author>Bilgen</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilgen, S. A.</author><author>Kilic, L.</author><author>Akdogan, A.</author><author>Kiraz, S.</author><author>Kalyoncu, U.</author><author>Karadag, O.</author><author>Ertenli, I.</author><author>Dogan, I.</author><author>Calguneri, M.</author></authors></contributors><auth-address>From the Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.</auth-address><titles><title>Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>358-62</pages><volume>17</volume><number>7</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1536-7355 (Electronic)
1076-1608 (Linking)</isbn><accession-num>21946459</accession-num><urls><related-urls><url> attacksBack painProteinuriaUInfliximab 5mg/kg0,2,6 weeks and 6th-8th weekAt least 12 mNo attackImprovement in proteinuriaN/AM694V/-Bilgenet al ADDIN EN.CITE <EndNote><Cite><Author>Bilgen</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilgen, S. A.</author><author>Kilic, L.</author><author>Akdogan, A.</author><author>Kiraz, S.</author><author>Kalyoncu, U.</author><author>Karadag, O.</author><author>Ertenli, I.</author><author>Dogan, I.</author><author>Calguneri, M.</author></authors></contributors><auth-address>From the Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.</auth-address><titles><title>Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>358-62</pages><volume>17</volume><number>7</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1536-7355 (Electronic)
1076-1608 (Linking)</isbn><accession-num>21946459</accession-num><urls><related-urls><url> attacksBack painPeripheral arthritisUEtanercept 25 mg twice a weekAt least 12 mNo attacksNo peripheral arthritisPosN/ABilgenet al ADDIN EN.CITE <EndNote><Cite><Author>Bilgen</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilgen, S. A.</author><author>Kilic, L.</author><author>Akdogan, A.</author><author>Kiraz, S.</author><author>Kalyoncu, U.</author><author>Karadag, O.</author><author>Ertenli, I.</author><author>Dogan, I.</author><author>Calguneri, M.</author></authors></contributors><auth-address>From the Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.</auth-address><titles><title>Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>358-62</pages><volume>17</volume><number>7</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1536-7355 (Electronic)
1076-1608 (Linking)</isbn><accession-num>21946459</accession-num><urls><related-urls><url> attacksBack painPeripheral arthritisLREtanercept 25 mg twice a weekAt least 12 mNo attacksNo peripheral arthritisN/AM694V/M6801IBilgenet al ADDIN EN.CITE <EndNote><Cite><Author>Bilgen</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilgen, S. A.</author><author>Kilic, L.</author><author>Akdogan, A.</author><author>Kiraz, S.</author><author>Kalyoncu, U.</author><author>Karadag, O.</author><author>Ertenli, I.</author><author>Dogan, I.</author><author>Calguneri, M.</author></authors></contributors><auth-address>From the Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.</auth-address><titles><title>Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment</title><secondary-title>J Clin Rheumatol</secondary-title></titles><periodical><full-title>J Clin Rheumatol</full-title></periodical><pages>358-62</pages><volume>17</volume><number>7</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1536-7355 (Electronic)
1076-1608 (Linking)</isbn><accession-num>21946459</accession-num><urls><related-urls><url> attacksBack painPeripheral arthritisLRInfliximab 5mg/kg0,2,6 weeks and 6th-8th weekAt least 12 mNo attacksNo peripheral arthritisposM694V/M694VCalligaris et al ADDIN EN.CITE <EndNote><Cite><Author>Calligaris</Author><Year>2008</Year><RecNum>34</RecNum><DisplayText><style face="superscript">11</style></DisplayText><record><rec-number>34</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">34</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Calligaris, L.</author><author>Marchetti, F.</author><author>Tommasini, A.</author><author>Ventura, A.</author></authors></contributors><auth-address>Department of Pediatrics, Institute of Child Health, Children's Hospital IRCCS Burlo Garofolo, Via dell'Istria 65/1, 34137 Trieste, Italy.</auth-address><titles><title>The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever</title><secondary-title>Eur J Pediatr</secondary-title></titles><periodical><full-title>Eur J Pediatr</full-title></periodical><pages>695-6</pages><volume>167</volume><number>6</number><edition>2007/06/26</edition><keywords><keyword>Adolescent</keyword><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Colchicine/pharmacology/therapeutic use</keyword><keyword>Drug Resistance</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Gout Suppressants/pharmacology/therapeutic use</keyword><keyword>Humans</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword></keywords><dates><year>2008</year><pub-dates><date>Jun</date></pub-dates></dates><isbn>0340-6199 (Print)
0340-6199 (Linking)</isbn><accession-num>17588171</accession-num><urls><related-urls><url> attacksChest attacksUAnakinra 50 mg/day 15 mNo attacksN/AN/ABelkhir et al ADDIN EN.CITE <EndNote><Cite><Author>Belkhir</Author><Year>2007</Year><RecNum>61</RecNum><DisplayText><style face="superscript">26</style></DisplayText><record><rec-number>61</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">61</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Belkhir, R.</author><author>Moulonguet-Doleris, L.</author><author>Hachulla, E.</author><author>Prinseau, J.</author><author>Baglin, A.</author><author>Hanslik, T.</author></authors></contributors><titles><title>Treatment of familial Mediterranean fever with anakinra</title><secondary-title>Ann Intern Med</secondary-title></titles><periodical><full-title>Ann Intern Med</full-title></periodical><pages>825-6</pages><volume>146</volume><number>11</number><edition>2007/06/06</edition><keywords><keyword>Aged</keyword><keyword>C-Reactive Protein/metabolism</keyword><keyword>Colchicine/therapeutic use</keyword><keyword>Drug Therapy, Combination</keyword><keyword>Familial Mediterranean Fever/blood/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword><keyword>Serum Amyloid A Protein/metabolism</keyword></keywords><dates><year>2007</year><pub-dates><date>Jun 5</date></pub-dates></dates><isbn>1539-3704 (Electronic)
0003-4819 (Linking)</isbn><accession-num>17548423</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>262007FMFneuromyopathy68FAbdominal attacksNeuromyopathy (due to high colchicine dose)U/ SEAnakinra 100 mg/day5 mNo attacksNeuromyopathy resolvedHTN/AM694V/M694VGattringer et al2007FMF29FAbdominal attacksAnakinra 100 mg/dayAnd then 100mg/every second day5 mNo attacksN/AN/AGattringer et al ADDIN EN.CITE <EndNote><Cite><Author>Gattringer</Author><Year>2007</Year><RecNum>23</RecNum><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>23</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">23</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Gattringer, R.</author><author>Lagler, H.</author><author>Gattringer, K. B.</author><author>Knapp, S.</author><author>Burgmann, H.</author><author>Winkler, S.</author><author>Graninger, W.</author><author>Thalhammer, F.</author></authors></contributors><titles><title>Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky</title><secondary-title>Eur J Clin Invest</secondary-title></titles><periodical><full-title>Eur J Clin Invest</full-title></periodical><pages>912-4</pages><volume>37</volume><number>11</number><edition>2007/11/02</edition><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Colchicine/therapeutic use</keyword><keyword>Drug Resistance/drug effects</keyword><keyword>Familial Mediterranean Fever/drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword><keyword>Risk Factors</keyword><keyword>Treatment Outcome</keyword></keywords><dates><year>2007</year><pub-dates><date>Nov</date></pub-dates></dates><isbn>0014-2972 (Print)
0014-2972 (Linking)</isbn><accession-num>17973784</accession-num><urls><related-urls><url> [pii]
10.1111/j.1365-2362.2007.01868.x</electronic-resource-num><language>eng</language></record></Cite></EndNote>102007FMF32FAbdominal attacksUAnakinra 100 mg/day15 daysNo attacksSerious injection reactionInterstitial pneumoniaN/AM694V/M694VKuijk et al ADDIN EN.CITE <EndNote><Cite><Author>Kuijk</Author><Year>2007</Year><RecNum>32</RecNum><DisplayText><style face="superscript">27</style></DisplayText><record><rec-number>32</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">32</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kuijk, L. M.</author><author>Govers, A. M.</author><author>Frenkel, J.</author><author>Hofhuis, W. J.</author></authors></contributors><titles><title>Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra</title><secondary-title>Ann Rheum Dis</secondary-title></titles><periodical><full-title>Ann Rheum Dis</full-title></periodical><pages>1545-6</pages><volume>66</volume><number>11</number><edition>2007/10/16</edition><keywords><keyword>Adolescent</keyword><keyword>Colchicine/therapeutic use</keyword><keyword>Drug Resistance</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Inflammation Mediators/blood</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword></keywords><dates><year>2007</year><pub-dates><date>Nov</date></pub-dates></dates><isbn>0003-4967 (Print)
0003-4967 (Linking)</isbn><accession-num>17934085</accession-num><urls><related-urls><url> [pii]
10.1136/ard.2007.071498</electronic-resource-num><language>eng</language></record></Cite></EndNote>272007FMF14FAbdominal attacksArthritis attacksUAnakinra 100 mg/day4 mNo attacksN/AM694V/M694IMitrou-lis et al ADDIN EN.CITE <EndNote><Cite><Author>Mitroulis</Author><Year>2008</Year><RecNum>13</RecNum><DisplayText><style face="superscript">28</style></DisplayText><record><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">13</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mitroulis, I.</author><author>Papadopoulos, V. P.</author><author>Konstantinidis, T.</author><author>Ritis, K.</author></authors></contributors><auth-address>First Division of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.</auth-address><titles><title>Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient</title><secondary-title>Neth J Med</secondary-title></titles><periodical><full-title>Neth J Med</full-title></periodical><pages>489-91</pages><volume>66</volume><number>11</number><edition>2008/12/17</edition><keywords><keyword>Adult</keyword><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Colchicine/pharmacology/*therapeutic use</keyword><keyword>*Drug Resistance</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Gout Suppressants/pharmacology/*therapeutic use</keyword><keyword>Humans</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword><keyword>Male</keyword></keywords><dates><year>2008</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>0300-2977 (Print)
0300-2977 (Linking)</isbn><accession-num>19075317</accession-num><urls><related-urls><url> attacksUAnakinra 100 mg/day6 mAttack duration and frequency decreasedN/AM694V/M694VRoldan et al ADDIN EN.CITE <EndNote><Cite><Author>Roldan</Author><Year>2008</Year><RecNum>12</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>12</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">12</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Roldan, R.</author><author>Ruiz, A. M.</author><author>Miranda, M. D.</author><author>Collantes, E.</author></authors></contributors><auth-address>Rheumatology Department, Reina Sofia Hospital, Avenida Menendez Pidal s/n, 14004 Cordoba, Spain. peperosa@teleline.es</auth-address><titles><title>Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine</title><secondary-title>Joint Bone Spine</secondary-title></titles><periodical><full-title>Joint Bone Spine</full-title></periodical><pages>504-5</pages><volume>75</volume><number>4</number><edition>2008/06/11</edition><keywords><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Child</keyword><keyword>Colchicine/therapeutic use</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Humans</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword><keyword>Male</keyword><keyword>Treatment Outcome</keyword></keywords><dates><year>2008</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>1778-7254 (Electronic)
1297-319X (Linking)</isbn><accession-num>18541452</accession-num><urls><related-urls><url>(08)00109-7 [pii]
10.1016/j.jbspin.2008.04.001</electronic-resource-num><language>eng</language></record></Cite></EndNote>292008FMF9?MAbdominal attacksUrticarial rashUAnakinra 1mg/kg/day6 mNo attacksNo rashN/AE148Q/-Hennig et al ADDIN EN.CITE <EndNote><Cite><Author>Hennig</Author><Year>2010</Year><RecNum>19</RecNum><DisplayText><style face="superscript">30</style></DisplayText><record><rec-number>19</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">19</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hennig, S.</author><author>Bayegan, K.</author><author>Uffmann, M.</author><author>Thalhammer, F.</author><author>Winkler, S.</author></authors></contributors><auth-address>Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Waehringerguertel 18-20, 1090, Vienna, Austria.</auth-address><titles><title>Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra-case report and review</title><secondary-title>Rheumatol Int</secondary-title></titles><periodical><full-title>Rheumatol Int</full-title></periodical><edition>2010/03/31</edition><dates><year>2010</year><pub-dates><date>Mar 30</date></pub-dates></dates><isbn>1437-160X (Electronic)
0172-8172 (Linking)</isbn><accession-num>20352226</accession-num><urls><related-urls><url> transplantamyloidosisPneumoni35MPneumoniaU Anakinra 100 mg/dayAnd then 100 mg/every second or third dayN/APneumonia resolvedN/AN/AMoser et alPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Nb3NlcjwvQXV0aG9yPjxZZWFyPjIwMDk8L1llYXI+PFJl
Y051bT4yNzwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjMx
PC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+Mjc8L3JlYy1udW1iZXI+
PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJwc2RmNXN2cjlldHp6aWVwc3N5eGZk
dzR0dGZlcHZyNTJ4OWYiPjI3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9Ikpv
dXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhv
cj5Nb3NlciwgQy48L2F1dGhvcj48YXV0aG9yPlBvaGwsIEcuPC9hdXRob3I+PGF1dGhvcj5IYXNs
aW5nZXIsIEkuPC9hdXRob3I+PGF1dGhvcj5LbmFwcCwgUy48L2F1dGhvcj48YXV0aG9yPlJvd2N6
ZW5pbywgRC48L2F1dGhvcj48YXV0aG9yPlJ1c3NlbCwgVC48L2F1dGhvcj48YXV0aG9yPkxhY2ht
YW5uLCBILiBKLjwvYXV0aG9yPjxhdXRob3I+TGFuZywgVS48L2F1dGhvcj48YXV0aG9yPktvdmFy
aWssIEouPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+NnRo
IE1lZGljYWwgRGVwYXJ0bWVudCB3aXRoIE5lcGhyb2xvZ3kgYW5kIERpYWx5c2lzLCBXaWxoZWxt
aW5lbnNwaXRhbCwgMTE2MCBWaWVubmEsIE1vbnRsZWFydHN0cmFzc2UgMzcsIEF1c3RyaWEuIENo
cmlzdGlhbi5tb3Nlci5tZEBhb24uYXQ8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5TdWNj
ZXNzZnVsIHRyZWF0bWVudCBvZiBmYW1pbGlhbCBNZWRpdGVycmFuZWFuIGZldmVyIHdpdGggQW5h
a2lucmEgYW5kIG91dGNvbWUgYWZ0ZXIgcmVuYWwgdHJhbnNwbGFudGF0aW9uPC90aXRsZT48c2Vj
b25kYXJ5LXRpdGxlPk5lcGhyb2wgRGlhbCBUcmFuc3BsYW50PC9zZWNvbmRhcnktdGl0bGU+PC90
aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TmVwaHJvbCBEaWFsIFRyYW5zcGxhbnQ8L2Z1
bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz42NzYtODwvcGFnZXM+PHZvbHVtZT4yNDwvdm9s
dW1lPjxudW1iZXI+MjwvbnVtYmVyPjxlZGl0aW9uPjIwMDgvMTEvMjc8L2VkaXRpb24+PGtleXdv
cmRzPjxrZXl3b3JkPkFteWxvaWRvc2lzL2V0aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkNvbGNo
aWNpbmUvdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPkRydWcgUmVzaXN0YW5jZTwv
a2V5d29yZD48a2V5d29yZD5GYW1pbGlhbCBNZWRpdGVycmFuZWFuIEZldmVyL2NvbXBsaWNhdGlv
bnMvKmRydWcgdGhlcmFweS8qc3VyZ2VyeTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdv
cmQ+PGtleXdvcmQ+SW50ZXJsZXVraW4gMSBSZWNlcHRvciBBbnRhZ29uaXN0IFByb3RlaW4vKnRo
ZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5LaWRuZXkgRmFpbHVyZSwgQ2hyb25pYy9l
dGlvbG9neS9zdXJnZXJ5PC9rZXl3b3JkPjxrZXl3b3JkPipLaWRuZXkgVHJhbnNwbGFudGF0aW9u
PC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxlIEFnZWQ8L2tl
eXdvcmQ+PGtleXdvcmQ+VHJlYXRtZW50IE91dGNvbWU8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0
ZXM+PHllYXI+MjAwOTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkZlYjwvZGF0ZT48L3B1Yi1kYXRl
cz48L2RhdGVzPjxpc2JuPjE0NjAtMjM4NSAoRWxlY3Ryb25pYykmI3hEOzA5MzEtMDUwOSAoTGlu
a2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MTkwMzMyNDg8L2FjY2Vzc2lvbi1udW0+PHVybHM+
PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9lbnRyZXovcXVl
cnkuZmNnaT9jbWQ9UmV0cmlldmUmYW1wO2RiPVB1Yk1lZCZhbXA7ZG9wdD1DaXRhdGlvbiZhbXA7
bGlzdF91aWRzPTE5MDMzMjQ4PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmlj
LXJlc291cmNlLW51bT5nZm42NDYgW3BpaV0mI3hEOzEwLjEwOTMvbmR0L2dmbjY0NjwvZWxlY3Ry
b25pYy1yZXNvdXJjZS1udW0+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRl
PjwvRW5kTm90ZT5=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Nb3NlcjwvQXV0aG9yPjxZZWFyPjIwMDk8L1llYXI+PFJl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ADDIN EN.CITE.DATA 312009FMFKidney transplantamyloidosis47MRenal transplantationAbdominal painUAnakinra100 mg/ 3 times a week during hemodialysis and then 100 mg/week after transplantationMore than 12 mSymptoms resolvedN/AM694V/M694VAlpay et al2010 ADDIN EN.CITE <EndNote><Cite><Author>Alpay</Author><Year>2010</Year><RecNum>18</RecNum><DisplayText><style face="superscript">32</style></DisplayText><record><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">18</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Alpay, N.</author><author>Sumnu, A.</author><author>Caliskan, Y.</author><author>Yazici, H.</author><author>Turkmen, A.</author><author>Gul, A.</author></authors></contributors><auth-address>Department of Internal Medicine, Istanbul School of Medicine, Istanbul University, Capa, Istanbul, Turkey, nalpay@istanbul.edu.tr.</auth-address><titles><title>Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever</title><secondary-title>Rheumatol Int</secondary-title></titles><periodical><full-title>Rheumatol Int</full-title></periodical><edition>2010/04/14</edition><dates><year>2010</year><pub-dates><date>Apr 13</date></pub-dates></dates><isbn>1437-160X (Electronic)
0172-8172 (Linking)</isbn><accession-num>20386914</accession-num><urls><related-urls><url> transplantamyloidosis52FRenal transplantationDiarrhea, weight loss, fatigue, anorexiaUAnakinra 100mg/day2 mSymptoms resolvedN/AM694V/M694VBilginer et al ADDIN EN.CITE <EndNote><Cite><Author>Bilginer</Author><Year>2010</Year><RecNum>26</RecNum><DisplayText><style face="superscript">33</style></DisplayText><record><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bilginer, Y.</author><author>Ayaz, N. A.</author><author>Ozen, S.</author></authors></contributors><auth-address>Department of Pediatrics, Nephrology and Rheumatology Unit, Hacettepe University School of Medicine, Sihhiye, 06100, Ankara, Turkey.</auth-address><titles><title>Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease</title><secondary-title>Clin Rheumatol</secondary-title></titles><periodical><full-title>Clin Rheumatol</full-title></periodical><pages>209-10</pages><volume>29</volume><number>2</number><edition>2009/09/24</edition><keywords><keyword>Adolescent</keyword><keyword>Amyloidosis/diagnosis/*drug therapy/*etiology</keyword><keyword>Antirheumatic Agents/therapeutic use</keyword><keyword>Behcet Syndrome/*complications/drug therapy</keyword><keyword>Colchicine/therapeutic use</keyword><keyword>Drug Therapy, Combination</keyword><keyword>Familial Mediterranean Fever/*complications/drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword><keyword>Proteinuria/drug therapy/etiology</keyword><keyword>Treatment Outcome</keyword></keywords><dates><year>2010</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1434-9949 (Electronic)
0770-3198 (Linking)</isbn><accession-num>19774408</accession-num><urls><related-urls><url>’s DiseaseAmyloidosis17FAbdominal attacksProteinuriaArthritisSkin and mucosal lesionsUAnakinra 1mg/kg/day12 mNo attacksImprovement in proteinuria and skin mucosal lesionsN/AM694V/M694VPetropoulou et al 2010PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QZXRyb3BvdWxvdTwvQXV0aG9yPjxZZWFyPjIwMTA8L1ll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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QZXRyb3BvdWxvdTwvQXV0aG9yPjxZZWFyPjIwMTA8L1ll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ADDIN EN.CITE.DATA 34FMF Bone marrow transplantation22MAbdominal attacksArthritisSkin lesionsSEaAnakinra 100 mg/day4 mNo attacksN/AM694VMeinzeret al ADDIN EN.CITE <EndNote><Cite><Author>Meinzer</Author><Year>2011</Year><RecNum>2</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Meinzer, U.</author><author>Quartier, P.</author><author>Alexandra, J. F.</author><author>Hentgen, V.</author><author>Retornaz, F.</author><author>Kone-Paut, I.</author></authors></contributors><auth-address>Division of Paediatric Rheumatology and Division of Paediatrics, CEREMAI, Hopital de Bicetre; University of Paris Sud, Le Kremlin Bicetre Cedex, France.</auth-address><titles><title>Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature</title><secondary-title>Semin Arthritis Rheum</secondary-title></titles><periodical><full-title>Semin Arthritis Rheum</full-title></periodical><edition>2011/02/01</edition><dates><year>2011</year><pub-dates><date>Jan 28</date></pub-dates></dates><isbn>1532-866X (Electronic)
0049-0172 (Linking)</isbn><accession-num>21277619</accession-num><urls><related-urls><url>(10)00252-0 [pii]
10.1016/j.semarthrit.2010.11.003</electronic-resource-num><language>Eng</language></record></Cite></EndNote>352011FMF45FAbdominal attacksSEb Anakinra 100 mg/day18 mRare moderate attacks without feverN/AM694V/M694VMeinzeret al ADDIN EN.CITE <EndNote><Cite><Author>Meinzer</Author><Year>2011</Year><RecNum>2</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Meinzer, U.</author><author>Quartier, P.</author><author>Alexandra, J. F.</author><author>Hentgen, V.</author><author>Retornaz, F.</author><author>Kone-Paut, I.</author></authors></contributors><auth-address>Division of Paediatric Rheumatology and Division of Paediatrics, CEREMAI, Hopital de Bicetre; University of Paris Sud, Le Kremlin Bicetre Cedex, France.</auth-address><titles><title>Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature</title><secondary-title>Semin Arthritis Rheum</secondary-title></titles><periodical><full-title>Semin Arthritis Rheum</full-title></periodical><edition>2011/02/01</edition><dates><year>2011</year><pub-dates><date>Jan 28</date></pub-dates></dates><isbn>1532-866X (Electronic)
0049-0172 (Linking)</isbn><accession-num>21277619</accession-num><urls><related-urls><url>(10)00252-0 [pii]
10.1016/j.semarthrit.2010.11.003</electronic-resource-num><language>Eng</language></record></Cite></EndNote>352011FMF51MAbdominal attacksUAnakinra 100 mg/day13 mNo attacksN/AM694V/M694VMeinzeret al ADDIN EN.CITE <EndNote><Cite><Author>Meinzer</Author><Year>2011</Year><RecNum>2</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Meinzer, U.</author><author>Quartier, P.</author><author>Alexandra, J. F.</author><author>Hentgen, V.</author><author>Retornaz, F.</author><author>Kone-Paut, I.</author></authors></contributors><auth-address>Division of Paediatric Rheumatology and Division of Paediatrics, CEREMAI, Hopital de Bicetre; University of Paris Sud, Le Kremlin Bicetre Cedex, France.</auth-address><titles><title>Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature</title><secondary-title>Semin Arthritis Rheum</secondary-title></titles><periodical><full-title>Semin Arthritis Rheum</full-title></periodical><edition>2011/02/01</edition><dates><year>2011</year><pub-dates><date>Jan 28</date></pub-dates></dates><isbn>1532-866X (Electronic)
0049-0172 (Linking)</isbn><accession-num>21277619</accession-num><urls><related-urls><url>(10)00252-0 [pii]
10.1016/j.semarthrit.2010.11.003</electronic-resource-num><language>Eng</language></record></Cite></EndNote>352011FMF7FAbdominal attacksUCanakinumab (2 mg/kg)/8 wk5 mNo attacksN/AM694V/M694VMeinzeret al ADDIN EN.CITE <EndNote><Cite><Author>Meinzer</Author><Year>2011</Year><RecNum>2</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Meinzer, U.</author><author>Quartier, P.</author><author>Alexandra, J. F.</author><author>Hentgen, V.</author><author>Retornaz, F.</author><author>Kone-Paut, I.</author></authors></contributors><auth-address>Division of Paediatric Rheumatology and Division of Paediatrics, CEREMAI, Hopital de Bicetre; University of Paris Sud, Le Kremlin Bicetre Cedex, France.</auth-address><titles><title>Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature</title><secondary-title>Semin Arthritis Rheum</secondary-title></titles><periodical><full-title>Semin Arthritis Rheum</full-title></periodical><edition>2011/02/01</edition><dates><year>2011</year><pub-dates><date>Jan 28</date></pub-dates></dates><isbn>1532-866X (Electronic)
0049-0172 (Linking)</isbn><accession-num>21277619</accession-num><urls><related-urls><url>(10)00252-0 [pii]
10.1016/j.semarthrit.2010.11.003</electronic-resource-num><language>Eng</language></record></Cite></EndNote>352011FMF7FAbdominal attacksUAnakinra 100 mg/day3 mNo attacksN/AM694V/M694VMeinzeret al ADDIN EN.CITE <EndNote><Cite><Author>Meinzer</Author><Year>2011</Year><RecNum>2</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Meinzer, U.</author><author>Quartier, P.</author><author>Alexandra, J. F.</author><author>Hentgen, V.</author><author>Retornaz, F.</author><author>Kone-Paut, I.</author></authors></contributors><auth-address>Division of Paediatric Rheumatology and Division of Paediatrics, CEREMAI, Hopital de Bicetre; University of Paris Sud, Le Kremlin Bicetre Cedex, France.</auth-address><titles><title>Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature</title><secondary-title>Semin Arthritis Rheum</secondary-title></titles><periodical><full-title>Semin Arthritis Rheum</full-title></periodical><edition>2011/02/01</edition><dates><year>2011</year><pub-dates><date>Jan 28</date></pub-dates></dates><isbn>1532-866X (Electronic)
0049-0172 (Linking)</isbn><accession-num>21277619</accession-num><urls><related-urls><url>(10)00252-0 [pii]
10.1016/j.semarthrit.2010.11.003</electronic-resource-num><language>Eng</language></record></Cite></EndNote>352011FMF7FAbdominal attacksUAnakinra 100 mg/day4 mNo attacksN/AI692de/V726 and E149QMeinzeret al ADDIN EN.CITE <EndNote><Cite><Author>Meinzer</Author><Year>2011</Year><RecNum>2</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Meinzer, U.</author><author>Quartier, P.</author><author>Alexandra, J. F.</author><author>Hentgen, V.</author><author>Retornaz, F.</author><author>Kone-Paut, I.</author></authors></contributors><auth-address>Division of Paediatric Rheumatology and Division of Paediatrics, CEREMAI, Hopital de Bicetre; University of Paris Sud, Le Kremlin Bicetre Cedex, France.</auth-address><titles><title>Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature</title><secondary-title>Semin Arthritis Rheum</secondary-title></titles><periodical><full-title>Semin Arthritis Rheum</full-title></periodical><edition>2011/02/01</edition><dates><year>2011</year><pub-dates><date>Jan 28</date></pub-dates></dates><isbn>1532-866X (Electronic)
0049-0172 (Linking)</isbn><accession-num>21277619</accession-num><urls><related-urls><url>(10)00252-0 [pii]
10.1016/j.semarthrit.2010.11.003</electronic-resource-num><language>Eng</language></record></Cite></EndNote>35 2011FMF12MSevere protracted myalgiaGeneralized convulsionsUAnakinra 100 mg/day8 mRapid clinical remissionN/AM694V/M694VMeinzeret al ADDIN EN.CITE <EndNote><Cite><Author>Meinzer</Author><Year>2011</Year><RecNum>2</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Meinzer, U.</author><author>Quartier, P.</author><author>Alexandra, J. F.</author><author>Hentgen, V.</author><author>Retornaz, F.</author><author>Kone-Paut, I.</author></authors></contributors><auth-address>Division of Paediatric Rheumatology and Division of Paediatrics, CEREMAI, Hopital de Bicetre; University of Paris Sud, Le Kremlin Bicetre Cedex, France.</auth-address><titles><title>Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature</title><secondary-title>Semin Arthritis Rheum</secondary-title></titles><periodical><full-title>Semin Arthritis Rheum</full-title></periodical><edition>2011/02/01</edition><dates><year>2011</year><pub-dates><date>Jan 28</date></pub-dates></dates><isbn>1532-866X (Electronic)
0049-0172 (Linking)</isbn><accession-num>21277619</accession-num><urls><related-urls><url>(10)00252-0 [pii]
10.1016/j.semarthrit.2010.11.003</electronic-resource-num><language>Eng</language></record></Cite></EndNote>352011FMF7MAbdominal attacksHenoch-Schonlein purpura (HSP)UAnakinra 100 mg/day(after 6 months Anakinra was discontinued because of improvement)Canakinumab 2 mg/kg/8 weeks16 m4 mRapid clinical remissionN/AM694V/M694VOzen et al ADDIN EN.CITE <EndNote><Cite><Author>Ozen</Author><Year>2011</Year><RecNum>11</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ozen, S.</author><author>Bilginer, Y.</author><author>Aktay Ayaz, N.</author><author>Calguneri, M.</author></authors></contributors><auth-address>Hacettepe University Faculty of Medicine, Ankara, Turkey. sezaozen@hacettepe.edu.tr</auth-address><titles><title>Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine</title><secondary-title>J Rheumatol</secondary-title></titles><periodical><full-title>J Rheumatol</full-title></periodical><pages>516-8</pages><volume>38</volume><number>3</number><edition>2010/12/17</edition><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Child</keyword><keyword>Colchicine/*therapeutic use</keyword><keyword>*Drug Resistance</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Immunoglobulin G/therapeutic use</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword><keyword>Interleukin-1/*immunology</keyword><keyword>Male</keyword><keyword>Receptors, Tumor Necrosis Factor/therapeutic use</keyword><keyword>Young Adult</keyword></keywords><dates><year>2011</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>0315-162X (Print)
0315-162X (Linking)</isbn><accession-num>21159830</accession-num><urls><related-urls><url> [pii]
10.3899/jrheum.100718</electronic-resource-num><language>eng</language></record></Cite></EndNote>362011FMFN/AFAbdominal attacksUAnakinra 1-2 mg/kg30 mAttack duration and frequency decreasedN/AM694V/M694VOzen et al ADDIN EN.CITE <EndNote><Cite><Author>Ozen</Author><Year>2011</Year><RecNum>11</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ozen, S.</author><author>Bilginer, Y.</author><author>Aktay Ayaz, N.</author><author>Calguneri, M.</author></authors></contributors><auth-address>Hacettepe University Faculty of Medicine, Ankara, Turkey. sezaozen@hacettepe.edu.tr</auth-address><titles><title>Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine</title><secondary-title>J Rheumatol</secondary-title></titles><periodical><full-title>J Rheumatol</full-title></periodical><pages>516-8</pages><volume>38</volume><number>3</number><edition>2010/12/17</edition><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Child</keyword><keyword>Colchicine/*therapeutic use</keyword><keyword>*Drug Resistance</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Immunoglobulin G/therapeutic use</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword><keyword>Interleukin-1/*immunology</keyword><keyword>Male</keyword><keyword>Receptors, Tumor Necrosis Factor/therapeutic use</keyword><keyword>Young Adult</keyword></keywords><dates><year>2011</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>0315-162X (Print)
0315-162X (Linking)</isbn><accession-num>21159830</accession-num><urls><related-urls><url> [pii]
10.3899/jrheum.100718</electronic-resource-num><language>eng</language></record></Cite></EndNote>362011FMFN/AMAbdominal attacksUAnakinra 1-2 mg/kg9 mNo attacksN/AM694V/M694VOzen et al ADDIN EN.CITE <EndNote><Cite><Author>Ozen</Author><Year>2011</Year><RecNum>11</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ozen, S.</author><author>Bilginer, Y.</author><author>Aktay Ayaz, N.</author><author>Calguneri, M.</author></authors></contributors><auth-address>Hacettepe University Faculty of Medicine, Ankara, Turkey. sezaozen@hacettepe.edu.tr</auth-address><titles><title>Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine</title><secondary-title>J Rheumatol</secondary-title></titles><periodical><full-title>J Rheumatol</full-title></periodical><pages>516-8</pages><volume>38</volume><number>3</number><edition>2010/12/17</edition><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Child</keyword><keyword>Colchicine/*therapeutic use</keyword><keyword>*Drug Resistance</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Immunoglobulin G/therapeutic use</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword><keyword>Interleukin-1/*immunology</keyword><keyword>Male</keyword><keyword>Receptors, Tumor Necrosis Factor/therapeutic use</keyword><keyword>Young Adult</keyword></keywords><dates><year>2011</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>0315-162X (Print)
0315-162X (Linking)</isbn><accession-num>21159830</accession-num><urls><related-urls><url> [pii]
10.3899/jrheum.100718</electronic-resource-num><language>eng</language></record></Cite></EndNote>362011FMFN/AFAbdominal attacksUEtanercept 0.8 mg/kg/week (for 3 months)Anakinra 1-2 mg/kg3 m2 m(insufficient clinical response)No attacksN/AM680I/M680IOzen et al ADDIN EN.CITE <EndNote><Cite><Author>Ozen</Author><Year>2011</Year><RecNum>11</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ozen, S.</author><author>Bilginer, Y.</author><author>Aktay Ayaz, N.</author><author>Calguneri, M.</author></authors></contributors><auth-address>Hacettepe University Faculty of Medicine, Ankara, Turkey. sezaozen@hacettepe.edu.tr</auth-address><titles><title>Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine</title><secondary-title>J Rheumatol</secondary-title></titles><periodical><full-title>J Rheumatol</full-title></periodical><pages>516-8</pages><volume>38</volume><number>3</number><edition>2010/12/17</edition><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Child</keyword><keyword>Colchicine/*therapeutic use</keyword><keyword>*Drug Resistance</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Immunoglobulin G/therapeutic use</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword><keyword>Interleukin-1/*immunology</keyword><keyword>Male</keyword><keyword>Receptors, Tumor Necrosis Factor/therapeutic use</keyword><keyword>Young Adult</keyword></keywords><dates><year>2011</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>0315-162X (Print)
0315-162X (Linking)</isbn><accession-num>21159830</accession-num><urls><related-urls><url> [pii]
10.3899/jrheum.100718</electronic-resource-num><language>eng</language></record></Cite></EndNote>362011FMFN/AMAbdominal attacksUEtanercept 0.8 mg/kg/week (for 6 months)Anakinra 1-2 mg/kg6 m7 m(insufficient clinical response)Attack duration and frequency decreasedN/AM6801I/M694VOzen et al ADDIN EN.CITE <EndNote><Cite><Author>Ozen</Author><Year>2011</Year><RecNum>11</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ozen, S.</author><author>Bilginer, Y.</author><author>Aktay Ayaz, N.</author><author>Calguneri, M.</author></authors></contributors><auth-address>Hacettepe University Faculty of Medicine, Ankara, Turkey. sezaozen@hacettepe.edu.tr</auth-address><titles><title>Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine</title><secondary-title>J Rheumatol</secondary-title></titles><periodical><full-title>J Rheumatol</full-title></periodical><pages>516-8</pages><volume>38</volume><number>3</number><edition>2010/12/17</edition><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Child</keyword><keyword>Colchicine/*therapeutic use</keyword><keyword>*Drug Resistance</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Immunoglobulin G/therapeutic use</keyword><keyword>Interleukin 1 Receptor Antagonist Protein/*therapeutic use</keyword><keyword>Interleukin-1/*immunology</keyword><keyword>Male</keyword><keyword>Receptors, Tumor Necrosis Factor/therapeutic use</keyword><keyword>Young Adult</keyword></keywords><dates><year>2011</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>0315-162X (Print)
0315-162X (Linking)</isbn><accession-num>21159830</accession-num><urls><related-urls><url> [pii]
10.3899/jrheum.100718</electronic-resource-num><language>eng</language></record></Cite></EndNote>362011FMFN/AFAbdominal attacksUEtanercept 0.8 mg/kg/week (for 6 months)Anakinra 1-2 mg/kg6 m9 m(insufficient clinical response)No attacksN/AM694V/M694VMitroulis et al ADDIN EN.CITE <EndNote><Cite><Author>Mitroulis</Author><Year>2011</Year><RecNum>37</RecNum><DisplayText><style face="superscript">37</style></DisplayText><record><rec-number>37</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">37</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mitroulis, I.</author><author>Skendros, P.</author><author>Oikonomou, A.</author><author>Tzioufas, A. G.</author><author>Ritis, K.</author></authors></contributors><titles><title>The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis</title><secondary-title>Ann Rheum Dis</secondary-title></titles><periodical><full-title>Ann Rheum Dis</full-title></periodical><pages>1347-8</pages><volume>70</volume><number>7</number><edition>2011/02/25</edition><keywords><keyword>Adult</keyword><keyword>Antibodies, Monoclonal/*therapeutic use</keyword><keyword>Antirheumatic Agents/*therapeutic use</keyword><keyword>Arthritis/*drug therapy</keyword><keyword>Familial Mediterranean Fever/*drug therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Interleukin-1beta/antagonists & inhibitors</keyword></keywords><dates><year>2011</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>1468-2060 (Electronic)
0003-4967 (Linking)</isbn><accession-num>21345814</accession-num><urls><related-urls><url> [pii]
10.1136/ard.2010.146878</electronic-resource-num><language>eng</language></record></Cite></EndNote>372011FMFProtacted arthritis25FAbdominal attacksArthritisUAnakinra 100 mg/dayEtanercept Canakinumab 150 mg 6 msevere injection reactionlong-term remission was not achievedno abdominal attacksresolution of arthritis and improved mobilityN/AM694V/M694VStonajovic et al ADDIN EN.CITE <EndNote><Cite><Author>Stankovic Stojanovic</Author><Year>2011</Year><RecNum>1</RecNum><DisplayText><style face="superscript">38</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Stankovic Stojanovic, K.</author><author>Delmas, Y.</author><author>Urena Torres, P.</author><author>Peltier, J.</author><author>Pelle, G.</author><author>Jeru, I.</author><author>Colombat, M.</author><author>Grateau, G.</author></authors></contributors><auth-address>1Service de medecine interne, hopital Tenon, Assistance publique Hopitaux de Paris (AP-HP), Universite Paris 6 Pierre et Marie Curie (UPMC), Paris, France.</auth-address><titles><title>Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure</title><secondary-title>Nephrol Dial Transplant</secondary-title></titles><periodical><full-title>Nephrol Dial Transplant</full-title></periodical><edition>2011/09/21</edition><dates><year>2011</year><pub-dates><date>Sep 29</date></pub-dates></dates><isbn>1460-2385 (Electronic)
0931-0509 (Linking)</isbn><accession-num>21931121</accession-num><urls><related-urls><url> [pii]
10.1093/ndt/gfr528</electronic-resource-num><language>Eng</language></record></Cite></EndNote>382012FMFAmyloidosisChron’s disease55FAbdominal attacksRenal failureChronic diarrheaUInfliximab Anakinra 100 mg/day6 m17 mNo responseComplete clinical remissionDiarrhea partially regressedRenal function was stableN/AM694V/M694VStonajovic et al ADDIN EN.CITE <EndNote><Cite><Author>Stankovic Stojanovic</Author><Year>2011</Year><RecNum>1</RecNum><DisplayText><style face="superscript">38</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Stankovic Stojanovic, K.</author><author>Delmas, Y.</author><author>Urena Torres, P.</author><author>Peltier, J.</author><author>Pelle, G.</author><author>Jeru, I.</author><author>Colombat, M.</author><author>Grateau, G.</author></authors></contributors><auth-address>1Service de medecine interne, hopital Tenon, Assistance publique Hopitaux de Paris (AP-HP), Universite Paris 6 Pierre et Marie Curie (UPMC), Paris, France.</auth-address><titles><title>Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure</title><secondary-title>Nephrol Dial Transplant</secondary-title></titles><periodical><full-title>Nephrol Dial Transplant</full-title></periodical><edition>2011/09/21</edition><dates><year>2011</year><pub-dates><date>Sep 29</date></pub-dates></dates><isbn>1460-2385 (Electronic)
0931-0509 (Linking)</isbn><accession-num>21931121</accession-num><urls><related-urls><url> [pii]
10.1093/ndt/gfr528</electronic-resource-num><language>Eng</language></record></Cite></EndNote>382012FMFAmyloidosisEnd-stage renal failure27MAbdominal attacksInflammatory anemiaUAnakinra 100mg/ three times a week7 mComplete clinical remissionN/AM694V/M694VStonajovic et al ADDIN EN.CITE <EndNote><Cite><Author>Stankovic Stojanovic</Author><Year>2011</Year><RecNum>1</RecNum><DisplayText><style face="superscript">38</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Stankovic Stojanovic, K.</author><author>Delmas, Y.</author><author>Urena Torres, P.</author><author>Peltier, J.</author><author>Pelle, G.</author><author>Jeru, I.</author><author>Colombat, M.</author><author>Grateau, G.</author></authors></contributors><auth-address>1Service de medecine interne, hopital Tenon, Assistance publique Hopitaux de Paris (AP-HP), Universite Paris 6 Pierre et Marie Curie (UPMC), Paris, France.</auth-address><titles><title>Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure</title><secondary-title>Nephrol Dial Transplant</secondary-title></titles><periodical><full-title>Nephrol Dial Transplant</full-title></periodical><edition>2011/09/21</edition><dates><year>2011</year><pub-dates><date>Sep 29</date></pub-dates></dates><isbn>1460-2385 (Electronic)
0931-0509 (Linking)</isbn><accession-num>21931121</accession-num><urls><related-urls><url> [pii]
10.1093/ndt/gfr528</electronic-resource-num><language>Eng</language></record></Cite></EndNote>382012FMFAmyloidosisEnd-stage renal failure27FAbdominal attacksAltered left ventricular functionUAnakinra 100mg/ three times a week18 mComplete remission of attacks and left ventricular functionN/AM694V/V726AStonajovic et al2012 ADDIN EN.CITE <EndNote><Cite><Author>Stankovic Stojanovic</Author><Year>2011</Year><RecNum>1</RecNum><DisplayText><style face="superscript">38</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Stankovic Stojanovic, K.</author><author>Delmas, Y.</author><author>Urena Torres, P.</author><author>Peltier, J.</author><author>Pelle, G.</author><author>Jeru, I.</author><author>Colombat, M.</author><author>Grateau, G.</author></authors></contributors><auth-address>1Service de medecine interne, hopital Tenon, Assistance publique Hopitaux de Paris (AP-HP), Universite Paris 6 Pierre et Marie Curie (UPMC), Paris, France.</auth-address><titles><title>Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure</title><secondary-title>Nephrol Dial Transplant</secondary-title></titles><periodical><full-title>Nephrol Dial Transplant</full-title></periodical><edition>2011/09/21</edition><dates><year>2011</year><pub-dates><date>Sep 29</date></pub-dates></dates><isbn>1460-2385 (Electronic)
0931-0509 (Linking)</isbn><accession-num>21931121</accession-num><urls><related-urls><url> [pii]
10.1093/ndt/gfr528</electronic-resource-num><language>Eng</language></record></Cite></EndNote>38FMFAmyloidosisEnd-stage renal failure61FAbdominal attacksUAnakinra 100mg/three times a week1000mg/day after transplantation8 mComplete remission of attacks N/AM694V/M694VHacihamdioglu et al ADDIN EN.CITE <EndNote><Cite><Author>Hacihamdioglu</Author><Year>2012</Year><RecNum>40</RecNum><DisplayText><style face="superscript">39</style></DisplayText><record><rec-number>40</rec-number><foreign-keys><key app="EN" db-id="psdf5svr9etzziepssyxfdw4ttfepvr52x9f">40</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hacihamdioglu, D. O.</author><author>Ozen, S.</author></authors></contributors><auth-address>Department of Pediatric Rheumatology, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey. sezaozen@hacettepe.edu.tr.</auth-address><titles><title>Canakinumab induces remission in a patient with resistant familial Mediterranean fever</title><secondary-title>Rheumatology (Oxford)</secondary-title></titles><periodical><full-title>Rheumatology (Oxford)</full-title></periodical><pages>1041</pages><volume>51</volume><number>6</number><edition>2012/03/10</edition><dates><year>2012</year><pub-dates><date>Jun</date></pub-dates></dates><isbn>1462-0332 (Electronic)
1462-0324 (Linking)</isbn><accession-num>22403182</accession-num><urls><related-urls><url> [pii]
10.1093/rheumatology/kes021</electronic-resource-num><language>eng</language></record></Cite></EndNote>392012FMFSacroiliitisChronic arthritis14FAbdominal attacksUEtanerceptAnakinra Canakinumab2 mNo responseResponded for 9 monthsNo attacksN/AM694V/M694Va (neutropenia, reduction ejection fraction)b (neuromyositis)U: unresponsiveR: responsiveLR: low responsiveI: intolerence SE: side effectm: monthN/A: not avaible F: female M:male ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- andy williams a time for us
- sherwin williams color of the year
- sherwin williams best neutrals 2019
- top sherwin williams neutral colors
- best sherwin williams cream colors
- best sherwin williams warm whites
- sherwin williams popular neutral colors
- sherwin williams paint names list
- top 10 sherwin williams colors
- sherwin williams most popular colors
- sherwin williams white paints
- most popular sherwin williams colors 2019